Method of treating factor IX deficiency using nuclease-mediated targeted integration
First Claim
Patent Images
1. A method for treating a Factor IX (F.IX) deficiency in a mammal, the method comprising:
- (i) intravenously administering one or more adeno-associated viral (AAV) vectors encoding a pair of zinc finger nucleases (ZFNs) or a pair of TAL-effector protein nucleases (TALENs) into a mammal with a F.IX deficiency such that a double-stranded break in an endogenous albumin gene occurs in liver cells of the mammal, and(ii) intravenously administering one or more AAV vectors comprising a donor sequence comprising a transgene encoding a functional F.IX protein into the mammal 1 to 3 days after administering the one or more AAV vectors encoding the pair of ZFNs or TALENs, wherein the transgene is flanked by nucleic acid sequences homologous to the albumin gene, such that the transgene is integrated into the endogenous albumin gene, the functional F.IX protein is expressed in liver cells of the mammal at increased levels as compared to mammals in which the AAV vectors of (i) and (ii) are administered on the same day.
2 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are methods and compositions for targeted, nuclease-mediated insertion of transgene sequences into the genome of a cell.
-
Citations
3 Claims
-
1. A method for treating a Factor IX (F.IX) deficiency in a mammal, the method comprising:
-
(i) intravenously administering one or more adeno-associated viral (AAV) vectors encoding a pair of zinc finger nucleases (ZFNs) or a pair of TAL-effector protein nucleases (TALENs) into a mammal with a F.IX deficiency such that a double-stranded break in an endogenous albumin gene occurs in liver cells of the mammal, and (ii) intravenously administering one or more AAV vectors comprising a donor sequence comprising a transgene encoding a functional F.IX protein into the mammal 1 to 3 days after administering the one or more AAV vectors encoding the pair of ZFNs or TALENs, wherein the transgene is flanked by nucleic acid sequences homologous to the albumin gene, such that the transgene is integrated into the endogenous albumin gene, the functional F.IX protein is expressed in liver cells of the mammal at increased levels as compared to mammals in which the AAV vectors of (i) and (ii) are administered on the same day. - View Dependent Claims (2, 3)
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeSangamo Therapeutics, Inc.
-
Original AssigneeSangamo Therapeutics, Inc.
-
InventorsHolmes, Michael C., Wechsler, Thomas
-
Primary Examiner(s)Wilson, Michael C
-
Application NumberUS14/630,128Publication NumberTime in Patent Office1,624 DaysField of Search435325, 435455, 424 931, 424 932, 424 9321US Class CurrentCPC Class CodesA61P 43/00 Drugs for specific purposes...A61P 7/04 Antihaemorrhagics; Procoagu...C12N 15/85 for animal cellsC12N 15/907 in mammalian cellsC12N 2750/14141 Use of virus, viral particl...
